Serena Ricciardi

Rome, Italy

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 51 publications

Lorlatinib in patients with ALK-positive metastatic NSCLC previously treated with an ALK inhibitor: results from a phase IV study.

Lorlatinib in patients with ALK-positive metastatic NSCLC previously treated with an ALK inhibitor: results from a phase IV study.

Journal: Future oncology (London, England)

Published: April 08, 2026

Advanced-stage ALK-positive non-small-cell lung cancer (NSCLC) patients: Real-world treatment patterns and outcomes from the Italian biomarker ATLAS database.

Advanced-stage ALK-positive non-small-cell lung cancer (NSCLC) patients: Real-world treatment patterns and outcomes from the Italian biomarker ATLAS database.

Journal: Lung cancer (Amsterdam, Netherlands)

Published: September 16, 2025

Braf-mutant metastatic non-small-cell lung cancer: Real world data from the Italian biomarker atlas database.

Braf-mutant metastatic non-small-cell lung cancer: Real world data from the Italian biomarker atlas database.

Journal: European journal of cancer (Oxford, England : 1990)

Published: June 02, 2025

TTF-1 Negativity Predicts Poor Outcomes in Advanced Non-Squamous NSCLC Also in the Immunotherapy Era: A Multicenter Cohort Study and Meta-Analysis.

TTF-1 Negativity Predicts Poor Outcomes in Advanced Non-Squamous NSCLC Also in the Immunotherapy Era: A Multicenter Cohort Study and Meta-Analysis.

Journal: Cancers

Published: May 15, 2025

A prospective study on clinicians' attitudes and survival outcomes for patients with advanced NSCLC and poor performance status in the immunotherapy era: PICASO (GOIRC-04-2020).

A prospective study on clinicians' attitudes and survival outcomes for patients with advanced NSCLC and poor performance status in the immunotherapy era: PICASO (GOIRC-04-2020).

Journal: Lung cancer (Amsterdam, Netherlands)

Published: February 14, 2025

An open-label, randomized phase III study of early switch maintenance vs delayed second-line nivolumab in advanced stage squamous non-small cell lung cancer (NSCLC) patients after standard first-line platinum-based chemotherapy-EDEN trial GOIRC 04-2016.

An open-label, randomized phase III study of early switch maintenance vs delayed second-line nivolumab in advanced stage squamous non-small cell lung cancer (NSCLC) patients after standard first-line platinum-based chemotherapy-EDEN trial GOIRC 04-2016.

Journal: Lung cancer (Amsterdam, Netherlands)

Published: May 06, 2024

A preliminary study on the diagnostic performance of the uPath PD-L1 (SP263) artificial intelligence (AI) algorithm in patients with NSCLC treated with PD-1/PD-L1 checkpoint blockade.

A preliminary study on the diagnostic performance of the uPath PD-L1 (SP263) artificial intelligence (AI) algorithm in patients with NSCLC treated with PD-1/PD-L1 checkpoint blockade.

Journal: Pathologica

Published: March 22, 2024

Characteristics and outcomes of immunotherapy-related liver injury in patients with hepatocellular carcinoma versus other advanced solid tumours.

Characteristics and outcomes of immunotherapy-related liver injury in patients with hepatocellular carcinoma versus other advanced solid tumours.

Journal: Journal of hepatology

Published: August 29, 2023

Management of the patient with extensive stage microcytoma. The importance of collaboration between oncology and radiotherapy.

Management of the patient with extensive stage microcytoma. The importance of collaboration between oncology and radiotherapy.

Journal: Recenti progressi in medicina

Published: July 01, 2023

Using peripheral immune-inflammatory blood markers in tumors treated with immune checkpoint inhibitors: An INVIDIa-2 study sub-analysis.

Using peripheral immune-inflammatory blood markers in tumors treated with immune checkpoint inhibitors: An INVIDIa-2 study sub-analysis.

Journal: iScience

Published: May 06, 2023

Impact of influenza vaccination on survival of patients with advanced cancer receiving immune checkpoint inhibitors (INVIDIa-2): final results of the multicentre, prospective, observational study.

Impact of influenza vaccination on survival of patients with advanced cancer receiving immune checkpoint inhibitors (INVIDIa-2): final results of the multicentre, prospective, observational study.

Journal: EClinicalMedicine

Published: March 07, 2023

Addition of Bevacizumab to Erlotinib as First-Line Treatment of Patients With EGFR-Mutated Advanced Nonsquamous NSCLC: The BEVERLY Multicenter Randomized Phase 3 Trial.

Addition of Bevacizumab to Erlotinib as First-Line Treatment of Patients With EGFR-Mutated Advanced Nonsquamous NSCLC: The BEVERLY Multicenter Randomized Phase 3 Trial.

Journal: Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer

Published: May 11, 2022

Showing 1-12 of 51

Last Updated: 09/26/2026